Atherosclerosis susceptibility

Disease ID:92
Name:Atherosclerosis susceptibility
Associated with:7 targets
0 immuno-relevant targets
0 immuno-relevant ligands
Database Links
Disease Ontology: DOID:1936
OMIM: 108725

Targets

BLT1 receptor
References:  1-3,12
Peroxisome proliferator-activated receptor-β/δ
Role:  Controversial
Comments:  Deletion of PPAR-beta/delta from foam cells increases the availability of inflammatory suppressors, which in turn reduces atherosclerotic lesion area, but Li et al. show that PPAR beta specific agonist failed to inhibit lesion formation.
References:  4-5,7-8
Peroxisome proliferator-activated receptor-γ
Comments:  Alteration at the receptor level: stimulated expression in atherosclerotic lesions, in macrophages and monocytic cell lines
References:  6,11
regulator of G-protein signaling 1
Comments:  Vascular diseases: Atherosclerosis AND aortic aneurysms
References:  9-10

Ligands

No ligand related data available for Atherosclerosis susceptibility

References

Show »

1. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. (2002) Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol., 22 (3): 443-9. [PMID:11884288]

2. Bäck M, Bu DX, Bränström R, Sheikine Y, Yan ZQ, Hansson GK. (2005) Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc. Natl. Acad. Sci. U.S.A., 102 (48): 17501-6. [PMID:16293697]

3. Bäck M, Hansson GK. (2006) Leukotriene receptors in atherosclerosis. Ann. Med., 38 (7): 493-502. [PMID:17101540]

4. Desvergne B, Michalik L, Wahli W. (2004) Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol. Endocrinol., 18 (6): 1321-32. [PMID:15087471]

5. Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L. (2005) The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis, 181 (1): 29-37. [PMID:15939051]

6. Kersten S, Desvergne B, Wahli W. (2000) Roles of PPARs in health and disease. Nature, 405 (6785): 421-4. [PMID:10839530]

7. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science, 302 (5644): 453-7. [PMID:12970571]

8. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. (2004) Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest., 114 (11): 1564-76. [PMID:15578089]

9. Patel J, Channon KM, McNeill E. (2013) The downstream regulation of chemokine receptor signalling: implications for atherosclerosis. Mediators Inflamm., 2013: 459520. [PMID:23690662]

10. Patel J, McNeill E, Douglas G, Hale AB, de Bono J, Lee R, Iqbal AJ, Regan-Komito D, Stylianou E, Greaves DR et al.. (2015) RGS1 regulates myeloid cell accumulation in atherosclerosis and aortic aneurysm rupture through altered chemokine signalling. Nat Commun, 6: 6614. [PMID:25782711]

11. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U.S.A., 95 (13): 7614-9. [PMID:9636198]

12. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. (2004) Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol., 24 (2): 369-75. [PMID:14656734]